Partly similar to the above studies, our study showed that CDC42 was negatively associated with TC, LDL-C, CRP, multivessel disease, and ACC/AHA type B2/C lesions in DCB-treated SV-CAD patients. Here, CDC42 is linked to glycogen storage disease VI.